← All peptides

Cagrilintide

Long-acting amylin analog. Appetite suppression research.

Route
SUBQ
Typical dose range
1 mg to 2.4 mg
Frequency
weekly
Half-life
7.5 days
Cycle on / off (days)
84 / 28
Evidence grade
B

What Cagrilintide is

Cagrilintide is long-acting amylin analog. appetite suppression research. It sits within metabolic research (appetite, glycemic control, body composition). Pepture keeps Cagrilintide in the library as a tracking target only, the app records what you enter but makes no recommendation about whether the compound is appropriate for you. That decision belongs with a licensed clinician.

Published pharmacokinetic data places the half-life of Cagrilintide at roughly 7.5 days, and doses recorded in the community cluster around the 1 mg to 2.4 mg range. Individual protocols vary widely. Jurisdictional status (FDA-approved, prescription, or research only) depends on the specific formulation and country.

How people track Cagrilintide

In Pepture, Cagrilintide is typically logged alongside fasted weight, waist, appetite score, fasting glucose, so cycle impact can be reviewed at the end of a block rather than by memory. The app captures dose, site, reconstitution ratio, cycle day, and any subjective rating you choose to add.

If you are considering Cagrilintide but have not started, or if you have started and want a second opinion, speak with a licensed clinician before changing any dose or cycle pattern.

Reconstitution math

Open the pre-filled Cagrilintide reconstitution calculator to compute syringe units per dose.

Reported Side Effects of Cagrilintide

Effects below are summarised from peer-reviewed literature or regulatory labeling where it exists. Not medical advice. Individual responses vary.

  • Nausea, vomiting, and diarrhea, especially during dose titration DailyMed
  • Constipation and early satiety DailyMed
  • Injection-site reactions including redness and induration FDA label
  • Gallbladder-related events (cholelithiasis, cholecystitis) reported in pivotal trials NEJM
  • Risk of pancreatitis (discontinue if suspected) FDA label
  • Contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2 FDA boxed warning

Used in these Pepture routines

Cagrilintide appears in the following Pepture stack templates. Tap to load the full routine.

Compare Cagrilintide

How Cagrilintide stacks up against the peers most users consider.